Search Results
Your search for world matches 4351 pages
Showing 51 - 100Prostate Cancer: Does Taking ARPIs and Anticoagulants Together Raise Risks?
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors (ARPIs) and different types of anticoagulants, investigators found no evidence of an increase in patients’ bleeding or clotting risks, despite previous lab results that raised alarms. These findings were...
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published in the Journal of Clinical Oncology.1 “Mandatory and uniform reporting of all [venous and arterial...
Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care
In time for the assigned deadline of February 23, 2026, medical societies, companies, health-care systems, and more have responded to a request for information from the Department of Health and Human Services (HHS) regarding the use of artificial intelligence (AI) in clinical practice. The Request...
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsored by a pharmaceutical company with an interest in prostate cancer treatments, extolled the virtues ...
Long-Term Health Risks for Testicular Cancer Survivors Differ by Chemotherapy Regimen
Long-term effects on renal function, cardiovascular risk, and overall health burden in survivors of testicular cancer differed according to the chemotherapy regimen each patient received, according to the results of a large real-world study published in JNCCN—Journal of the National Comprehensive...
Leader in Global Cancer Care, Paul E. Goss, MD, PhD, FRCPC, FRCP Dies at 70
The oncology community is mourning the loss of Paul E. Goss, MD, PhD, FRCPC, FRCP, who died on December 19, 2025, at his home in Hopkinton, Massachusetts, from multiple system atrophy—a rare, progressive neurologic disorder with symptoms resembling those of Parkinson’s disease. He was 70 years ...
Introducing ASCO AI in Oncology
In February, ASCO and Conexiant launched ASCO AI in Oncology (ascoai.org), a digital platform dedicated to understanding how artificial intelligence (AI) is impacting cancer care. “Our goal with this hub is to empower oncology professionals with knowledge and the tools to adapt to a rapidly...
ASCO’s First Living Guideline in GU Cancers Reflects Recent Practice-Changing Trials on Systemic Treatment of mCRPC
ASCO has published an updated guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), representing ASCO’s first Living Guideline in the area of prostate cancer and the first in any genitourinary (GU) cancer.1 “Guidelines will become less useful if...
Proximity to Nuclear Power Plants and Cancer Risk
U.S. counties located closer to operational nuclear power plants (NPPs) have higher rates of cancer mortality than those located farther away, according to a new study published by Alwadi et al in Nature Communications. The study is the first of the 21st century to analyze proximity to NPPs and...
FDA Approves Once-Monthly Dosing Schedule for Amivantamab and Hyaluronidase-lpuj
Today, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro). When administered in combination with oral lazertinib for the first-line treatment EGFR-mutated...
COA Survey Shows Insurer Utilization Management Interferes With Cancer Treatment Decisions
A national survey of independent community oncology practices has found that utilization management tactics imposed by health insurers and pharmacy benefit managers (PBMs) delay cancer treatment, interfere with physician-directed care, and increase administrative and financial burdens on practices...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
ASCO and Conexiant Launch ASCO AI in Oncology
The American Society of Clinical Oncology (ASCO®) and Conexiant today announced the launch of ASCO AI in Oncology, a premier digital destination designed to help oncology professionals navigate the transformative role of artificial intelligence (AI) in cancer care. Launching this initiative marks...
A New Risk Model for Esophagectomy Draws on the STS National Database
A nationwide, real-world analysis using the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) from 2012 to 2023 evaluated over 16,000 adults who underwent esophagectomy for primary esophageal cancer to develop and validate a long-term all-cause mortality risk model. The...
Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy
The first unified, pan-tumor guideline framework has been released for how pathologists should evaluate and score response in the neoadjuvant setting. These consensus guidelines, which were a joint effort by the Society for Immunotherapy of Cancer's (SITC) Pan-tumor Harmonization of Pathologic...
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
Breakthrough research presented at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting shows that additional lymph node evaluation is needed during surgery for non–small cell lung cancer (NSCLC) to accurately identify cancer spread (Abstract A-1588). Globally, surgical standards vary on the...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
WHO Analysis Finds Nearly 40% of Global Cancer Cases Attributable to Modifiable Risk Factors
Almost 40% of all new cancer cases could be attributed to at least one of 30 modifiable risk factors, according to a new global analysis from the World Health Organization (WHO) and its International Agency for Research on Cancer (IARC). The analysis of preventable cancers was published in Nature...
World Cancer Day 2026: UICC’s Campaign ‘United by Unique’
As the organizer of World Cancer Day on February 4, the Union for International Cancer Control (UICC) is mobilizing organizations and individuals worldwide to ensure that the voices of people affected by cancer are heard and drive a new vision of cancer care. Now in its second year, the World...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Leader in Global Cancer Care, Paul E. Goss, MD, PhD, Dies at 70
The oncology community is mourning the loss of Paul E. Goss, MD, PhD, who died on December 19, 2025, at his home in Hopkinton, Massachusetts, from multiple system atrophy—a rare, progressive neurologic disorder with symptoms resembling those of Parkinson’s disease. He was 70 years old. Born in...
HCC: LLM Advice and Treatment Concordance
Commonly used large language models (LLMs) were able to provide appropriate, guideline-aligned treatment recommendations for patients with straightforward cases of early-stage hepatocellular carcinoma; however, greater disagreement with physician recommendations was seen in cases of late-stage...
Global Cancer Survival Gaps Assessed Using a Country-Level Machine-Learning Framework
A machine-learning model has calculated country-specific cancer mortality-to-incidence ratios and evaluated the factors that contribute the most to each country's survival gaps. Additionally, the artificial intelligence (AI) tool mapped out actions each country could take to improve cancer...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
Scientists at several institutions across the country, in partnership with the Multiple Myeloma Research Foundation (MMRF), have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma. The findings, published by Pilcher et al in Nature Cancer, ...
Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
Steve Brown, Founder and Chief Executive Officer of CureWise (curewise.com), an artificial intelligence (AI)-driven patient advocacy app, describes his year-long quest to understand a series of symptoms that ultimately led to a diagnosis of light chain (AL) amyloidosis—a disease closely related to ...
Study Finds GLP-1 RAs May Influence Colorectal Cancer Mortality
Colon cancer is among the leading causes of cancer-related morbidity and mortality both in the United States and globally. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may influence cancer mortality, and the results from a new study may add to that mounting ...
Do GLP-1 RAs Reduce the Risk of Developing Colorectal Cancer More Than Aspirin?
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
Most People Trust AI Less Than Physicians, Survey Finds
Two national surveys examining trust and acceptance of medical artificial intelligence (AI) have found that while most people are reluctant to use AI tools to diagnose their health condition, they see potential in the technology’s ability to help diagnose cancer. The findings, published by Sobolev...
HCC: Real-World Patterns of Systemic Therapy, Sequencing, and Survival
A recent retrospective cohort study has described the current treatment patterns, sequencing, and survival outcomes among patients receiving systemic therapy for hepatocellular carcinoma (HCC). The findings, which were published by Lau-Min et al in JAMA Network Open, showed that...
Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma
The flipped dose for nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of the immunotherapy combination in patients with advanced unresectable melanoma, according to...
Tanning Bed Exposure and Melanoma Risks
Research has elucidated how radiation from tanning beds increases the mutation burden across a broad area of melanocytes, thereby significantly raising the risk of developing melanoma. Findings published in Science Advances show that individuals who used tanning beds had a 2.85-fold higher risk of...
Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab
Andrew Portuguese, MD, of Fred Hutchinson Cancer Center, discusses findings from a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium looking at the real-world safety and efficacy of the BCMA-CD3 bispecific antibody elranatamab (Abstract 136).
Ironically, Smoking May Have Saved My Life
I was diagnosed with stage IV non-small cell lung (NSCLC) adenocarcinoma on August 1, 2013—World Lung Cancer Day. If it hadn’t been for an article that caught my eye the year before about the recommendation from the United States Preventive Services Task Force that all men aged 65 to 75 who have...
SIO 2025: The Future of Integrative Oncology
Guest Editor’s Note: In October, the Society for Integrative Oncology (SIO) held its annual international conference in Boston. The theme was “The Future of Integrative Oncology,” with presentations and workshops focused on evidence-based integrative therapies and innovative research methodologies. ...
Christine M. Lovly, MD, PhD, FASCO, Named Head, Thoracic Oncology, at City of Hope
Christine M. Lovly, MD, PhD, FASCO, an expert on lung cancer with almost 2 decades of experience in clinical care, translational research, and academic leadership, will spearhead the new national thoracic oncology program at City of Hope in Duarte, California. In her new role, effective January 1, ...
Integrating Mental Health Into Cancer Care: A Community Oncology Imperative
When Julie began chemotherapy for breast cancer, her oncologist adjusted antiemetics weekly and carefully tracked neutrophil counts. Still, no one asked about the panic attacks that kept her awake at night. She told herself this was just part of cancer. It was not until she stopped showing up for...
UICC’s World Cancer Declaration 2025–2035
The Union for International Cancer Control (UICC) published its World Cancer Declaration 2025–2035 framework on November 19, 2025.1 The declaration urges governments and policymakers to take decisive action to reduce the global burden of cancer; promote equitable access to prevention, diagnosis,...
The Diagnosis I Couldn’t Deliver: An Oncologist’s Journey Between Roles
As a medical oncologist and palliative care physician, I have spent years preparing for difficult conversations. I’ve guided patients and families through the uncertainty of cancer, helped them navigate complex decisions, and sought meaning amid shifting prognoses. As an academic, I teach future...
How AI Is Ushering in a New Era in Cancer Care
On October 30, 2025, Google Cloud held its second annual Cancer AI Symposium to explore how artificial intelligence (AI) is advancing cancer research, diagnosis, and treatment, in unparalleled ways. Held at Google’s St. John’s Terminal office in New York City, the event brought together leaders in...
Building the Cancer Care Africa Deserves
There is something deeply moving about watching hope take shape, not as a slogan or a speech, but as people coming together to build the cancer care Africa deserves. The African Organization for Research and Training in Cancer (AORTIC) 2025 Congress in Tunisia held in November was a vivid reminder...
Validation of Pathology-AI Integration Tool for Risk Stratification in Locally Advanced Colon Cancer Without Chemotherapy
The Combined Analysis of Pathology and Artificial Intelligence (AI; CAPAI) model effectively stratified patients with colon cancer into distinct prognostic groups, identifying nearly half as low-risk, with “favorable” cancer-specific survival outcomes in the absence of adjuvant chemotherapy,...
Aaron Logan, MD, PhD, on Relapsed/Refractory B-Cell ALL: Real-World Data on Brexucabtagene Autoleucel and Transplant
Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract...
Renuka Iyer, MD, Named New Chief Medical Officer for NCCN
The National Comprehensive Cancer Network® (NCCN®) has announced the hiring of Renuka Iyer, MD, as the new Chief Medical Officer (CMO) for the organization. Dr. Iyer has a long history of leadership and innovation in oncology. She currently serves as a Professor of Oncology for Roswell Park...
Upfront Reduced-Dose Enfortumab Vedotin With Pembrolizumab in First-Line Treatment of Advanced Urothelial Cancer
In a U.S. retrospective cohort study reported in JAMA Oncology, Chow et al found that reduced-dose vs standard upfront enfortumab vedotin-ejfv plus pembrolizumab reduced the risk of enfortumab vedotin treatment interruption in the first-line treatment of patients with advanced urothelial cancer....
Survey Finds Global Embrace of Integrative Cancer Care
Around the world, doctors, nurses, and pharmacists are turning to evidence-based integrative approaches such as acupuncture, yoga, exercise, massage, and nutrition counseling to help people with cancer manage the harsh side effects of treatment, according to the results of a recent survey. The new...
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surgery in patients with lung cancer, especially in stage I, and showed correlations with established...
Project DISARM: New Cancer Mission Emphasizes Risk Assessment and Early Detection of Ovarian Cancer
Often referred to as a “silent killer,” ovarian cancer is the most lethal of female cancers. Issues of late detection and poor survival rates continue to persevere, leading to increasing levels of incidence and mortality. Data from the World Ovarian Cancer Coalition have stressed that ovarian...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
Treatment Advances in Malignant Hematology: 2025 Updates
The pace of therapeutic innovation in hematologic oncology continues to accelerate, moving clinical practice away from broad-spectrum chemotherapy and toward an era of highly personalized, biologically driven treatment. This transformation was the central theme of the 2025 National Comprehensive...
